Imugene’s azer-cel shows promise in treating relapsed DLBCL
The company reported that six of seven patients reached complete remission, resulting in a 55% complete response rate.
News
Elegen, Nutcracker unveil cell-free RNA manufacturing pilot
CEL-SCI collaboration to advance Multikine access in Saudi Arabia
AbbVie, IGI sign licensing deal for cancer drug ISB 2001
EC approves Tevimbra plus chemo to treat nasopharyngeal cancer
Bayer’s elinzanetant receives UK approval for menopause symptoms
Merck to acquire UK drugmaker Verona Pharma for $10bn
Zentiva, Lupin collaborate on commercialising Certolizumab Pegol
